Interpace Biosciences, Inc. IDXG
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.14M | 36.24M | 38.73M | 41.91M | 45.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.14M | 36.24M | 38.73M | 41.91M | 45.45M |
| Cost of Revenue | 13.10M | 13.58M | 14.60M | 15.92M | 17.00M |
| Gross Profit | 23.04M | 22.66M | 24.13M | 25.99M | 28.45M |
| SG&A Expenses | 17.58M | 17.44M | 18.18M | 20.21M | 21.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.28M | 31.64M | 33.42M | 36.82M | 39.21M |
| Operating Income | 4.87M | 4.60M | 5.31M | 5.09M | 6.25M |
| Income Before Tax | 4.00M | 3.14M | 3.77M | 4.10M | 4.86M |
| Income Tax Expenses | -20.86M | -20.93M | -21.21M | -1.00K | 14.00K |
| Earnings from Continuing Operations | 24.86 | 24.06 | 24.98 | 4.10 | 4.84 |
| Earnings from Discontinued Operations | -413.00K | -412.00K | -409.00K | -298.00K | -280.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.45M | 23.65M | 24.58M | 3.80M | 4.56M |
| EBIT | 4.87M | 4.60M | 5.31M | 5.09M | 6.25M |
| EBITDA | 5.34M | 5.05M | 5.73M | 5.49M | 6.62M |
| EPS Basic | 26.79 | 26.04 | 27.75 | 3.78 | 4.65 |
| Normalized Basic EPS | 2.48 | 2.43 | 3.53 | 3.27 | 3.82 |
| EPS Diluted | 4.42 | 3.67 | 3.82 | 1.35 | 3.07 |
| Normalized Diluted EPS | 0.53 | 0.49 | 0.56 | 0.42 | 1.56 |
| Average Basic Shares Outstanding | 11.87M | 7.21M | 3.54M | 3.54M | 3.53M |
| Average Diluted Shares Outstanding | 22.16M | 17.51M | 17.51M | 21.91M | 17.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |